Approved Through Ono Pharmaceutical

SK Biopharm announced on September 16 that its partner, Ono Pharmaceutical, has received new drug approval from the Japanese Ministry of Health, Labour and Welfare for the antiepileptic drug Cenobamate (Japanese brand name Exkiscopri).


Epilepsy treatment Cenobamate (US product name Xcopri). SK Biopharmaceuticals

Epilepsy treatment Cenobamate (US product name Xcopri). SK Biopharmaceuticals

View original image

Japan is the world's second-largest epilepsy market by individual country, following the United States. It is estimated that there are approximately one million patients. With this approval, Cenobamate has established a foothold for entering the Japanese market, which has a high level of unmet medical needs.


This approval is based on the results of a multinational Phase 3 clinical trial (YKP3089C035), which targeted adult patients with partial-onset epilepsy in Korea, China, and Japan. Cenobamate adjunctive therapy demonstrated a significant reduction in seizure frequency compared to placebo, meeting the primary endpoint.


SK Biopharm signed a licensing and commercialization agreement with Ono Pharmaceutical for Cenobamate in Japan in October 2020. Under this approval, the company will receive a contractual milestone payment and, in the future, royalties based on Japanese sales.


Cenobamate has received approval in more than 45 countries and regions worldwide, including the United States and Europe. In the United States, SK Biopharm's local subsidiary SK Life Science distributes the drug directly, while commercialization in other major markets is conducted through regional partnerships. In Japan, additional Phase 3 clinical trials are underway in adolescent and adult patients with primary generalized tonic-clonic seizures (PGTC) and pediatric patients with partial-onset seizures.



Lee Dong-hoon, CEO of SK Biopharm, stated, "With this approval, we have completed the foundation for entering the major Northeast Asian markets of Korea, China, and Japan. We will now focus on achieving commercialization results that lead to actual patient prescriptions in these markets."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing